



Axonics® to Present at Upcoming Investor Conferences

November 26, 2019

IRVINE, Calif.--(BUSINESS WIRE)--Nov. 26, 2019-- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable rechargeable sacral neuromodulation ("SNM") devices for the treatment of bladder and bowel dysfunction, today announced that members of the senior management team will present at the following upcoming investor conferences and will be available for meetings with institutional investors:

- Raymond W. Cohen, Chief Executive Officer, is scheduled for a fireside chat at the Piper Jaffray Healthcare Conference on Wednesday, December 4, at 10:30 am EST at the Lotte New York Palace in New York City.
- Cohen is also scheduled for a fireside chat at the Evercore ISI HealthCONx Conference on Thursday, December 5, at 2:00 pm EST at the Four Seasons Hotel in Boston.

To access the live webcast of the fireside chats at the aforementioned conferences, please visit the Events & Presentations page of the Investor Relations section of the Company's website at ir.axonics.com. A replay of the webcasts will be available shortly after the conclusion of the fireside chats and will be archived on the Company's website for 90 days.

About Axonics Modulation Technologies, Inc.

Axonics, based in Irvine, Calif., has developed and is commercializing novel implantable SNM devices for patients with urinary and bowel dysfunction. These conditions are caused by a miscommunication between the bladder and the brain and significantly impacts quality of life. Overactive bladder affects an estimated 87 million adults in the U.S. and Europe. Another estimated 40 million adults are reported to suffer from fecal incontinence/accidental bowel leakage. SNM therapy has been employed to reduce symptoms and restore pelvic floor function for the past two decades. Reimbursement coverage is well established in the U.S. and Europe. The Axonics System is the first rechargeable SNM system approved for sale in the U.S., Canada and Europe and the first to gain full-body MRI conditional labeling. For more information, visit the Company's website at www.axonics.com.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20191126005238/en/>

Source: Axonics Modulation Technologies, Inc.

Axonics' Contact

Axonics Modulation Technologies, Inc.
Dan Dearen, +1-949-396-6320
President & Chief Financial Officer
ir@axonics.com

Investor & Media Contact

W2Opure
Matt Clawson, +1-949-370-8500
mclawson@w2ogroup.com